Mirjam Hermisson
Overview
Explore the profile of Mirjam Hermisson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eberhardt O, Hermisson M, Eberle-Strauss G, Topka H
Neuroophthalmology
. 2019 Sep;
43(4):256-259.
PMID: 31528192
Third nerve palsy is bilateral in only about 10% of cases, of which one in five cases is due to brainstem stroke. Bilateral oculomotor nerve palsy as an isolated clinical...
2.
Schweneker K, Clemm C, Brugel M, Souvatzoglou M, Hermisson M, Schmidt-Graf F, et al.
Exp Hematol Oncol
. 2015 May;
3:29.
PMID: 25954595
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite the use of optimized first-line therapy, GBM is still associated with a poor prognosis and an...
3.
Bahr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Kortvelyessy P, et al.
Acta Neurochir (Wien)
. 2011 Sep;
154(2):229-35.
PMID: 21909835
Background: Levetiracetam (LEV) is a newer anticonvulsant with a favorable safety profile. There seem to be no relevant drug interactions, and an intravenous formulation is available. Therefore, LEV might be...
4.
Stupp R, Hegi M, Neyns B, Goldbrunner R, Schlegel U, Clement P, et al.
J Clin Oncol
. 2010 May;
28(16):2712-8.
PMID: 20439646
Purpose: Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and...
5.
Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, et al.
J Neurochem
. 2006 Jan;
96(3):766-76.
PMID: 16405512
Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease....
6.
Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, et al.
Onkologie
. 2005 Sep;
28(8-9):391-6.
PMID: 16160401
Background: The risk for patients with primary brain tumors of experiencing an epileptic seizure at least once in the course of disease probably exceeds 50%, depending on tumor location and...
7.
Wick W, Hermisson M, Kortmann R, Kuker W, Duffner F, Dichgans J, et al.
J Neurooncol
. 2002 Sep;
59(2):151-5.
PMID: 12241108
The median survival for patients with glioblastoma is 12 months. The authors evaluated whether preirradiation gemcitabine/treosulfan (GeT) chemotherapy followed by standard radiotherapy improved outcome in patients with glioblastoma. Seventeen patients...